Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Fable Media Group: Dividend Season, Four Times a Year - Redeye

Analys | Redeye

•

29 Aug 07:18

Fable Media Group: Dividend Season, Four Times a Year - Redeye

FluoGuide Q2 2025: Gearing up for the next phase - Redeye

Redeye comments on FluoGuide’s Q2 2025 report. The company’s recent progress update mostly aligned w...

Systemair Q1 2025/26: First impression - Redeye

Devyser: Partnering for channel coverage of RHD test in the US - Redeye

Redeye comments on the now confirmed partnering with industry giant Quest Diagnostics for channel co...

Alzinova: Innovative new approach to Alzheimer’s - Edison

Lipum Q2: Focus on securing funding - Redeye

Redeye provides a research update following the Q2 report published by Lipum earlier today.

Jumpgate Q2 2025: Slightly softer sales but good cost control - Redeye

Nekkar Q2 2025: Top-line Beat While Elevated Costs Pressure Profitability - Redeye

Redeye comments on Nekkar’s Q2 report, that presented mixed Q2 figures during a relatively slow peri...

MindArk Q2 2025: Sequential Rebound with a Positive Outlook - Redeye

Fable Media Group Q2 2025: Solid execution in a tough market - Redeye

Redeye comments on Fable Media Group’s Q2 results, aligning with the preliminary figures and our est...

Fable Media

Analys | Analysguiden

•

28 Aug 08:53

Train Alliance: Framåt på flera fronter - Analysguiden

Double Bond Pharma: Lovande cancerprojekt i startblocken - Mangold Insight Analys

Double Bond Pharmaceutical utvecklar läkemedelskandidaten SI-053, för behandling av glioblastom, en ...

GiG Software Q2 2025: Results as expected, trimmed guidance - Redeye

Nanexa: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Emergers

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with...

Vibrosense Dynamics: Rapportkommentar Q4’24/25 - Kalqyl

AcouSort Q2: Robust cost control - Redeye

Redeye provides an in-depth review of AcouSort’s Q2 report and activities during and after the quart...

GomSpace Q2 Review: Orbiting Higher - Redeye

Smart Eye: On the Autobahn to 2026 - Redeye

Redeye updates its estimates on Smart Eye following the Q2 2025 report.

BICO Group: A Forgotten Darling with Turnaround Potential - Redeye

CLS: Correction to our estimates - Redeye

Redeye makes a correction to our estimates, slightly impacting our fair value range.

Clinical Laserthermia

Analys | Redeye

•

28 Aug 07:23

Faron Pharmaceuticals H1: Advancing to registrational trials - Redeye

Faron Pharmaceuticals

Analys | ABG Sundal Collier

•

28 Aug 07:23

Inission: Q2 likely marked the R12m EBITA trough - ABG

* Enedo drove the 6% Q2 adj. EBITA miss while Inission beat by 4% * 1.

Inission

Analys | ABG Sundal Collier

•

27 Aug 15:51

BTS Group: North America turnaround in focus - ABG

BTS Group

Analys | ABG Sundal Collier

•

27 Aug 14:29

INVISIO: Positive outlook comments from peers - ABG

* CEOTRONICS and GN's FalCom seem to perform well..

Invisio

Analys | Analysguiden

•

27 Aug 14:28

ByggPartnerGruppen: Fortsätter på inslagen väg - Analysguiden

Atria: EUR 16m modernisation investment - aims for EUR 3m annual savings - Nordea

Atria plans EUR 16m investment in its Kauhajoki plant to modernise production and reorganise beef pr...

BioInvent Q2 2025: Narrowed Focus on BI-1206 and BI-1808 - Redeye

Thunderful Q2 2025: Atari overshadows operations - Redeye

Redeye comments on the Q2 report. Top-line figures came in broadly in line with our expectations.

Premium Snacks: Rapportkommentar Q2’25 - Kalqyl

Premium Snacks

Analys | Analysguiden

•

27 Aug 11:10

Expres2ion Biotech: Rekrytering startar i fas 1 - Analysguiden

ExpreS2ion Biotechnologies driver en fas 1-studie med vaccinkandidaten ES2B-C001 på patienter med HE...

ExpreS2ion Biotech

Föregående Nästa